BPI Double Nickase Plasmid (h): sc-404909-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BPI Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- BPI Double Nickase Plasmid (h) and BPI Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting BPI. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BPI Antibody (H-10): sc-514212
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BPI Double Nickase Plasmid (h) | sc-404909-NIC | 20 µg | $410.00 | |||
BPI Double Nickase Plasmid (h2) | sc-404909-NIC-2 | 20 µg | $410.00 |
Human BPI (bactericidal/permeability-increasing protein) is a neutrophil granule protein that binds lipopolysaccharide (LPS) on Gram-negative bacteria, neutralizing endotoxin activity and promoting bacterial killing. It participates in innate immune defense at mucosal and systemic sites by modulating inflammatory signaling downstream of LPS recognition, including pathways that converge on cytokine production and myeloid activation. Variation in BPI expression or function has been studied in the context of inflammatory airway disease, cystic fibrosis–associated infections, sepsis-related endotoxemia, and other conditions where dysregulated host–pathogen interactions contribute to pathology. Experimental perturbation of BPI supports mechanistic studies of antimicrobial barrier function, neutrophil biology, and LPS-driven inflammatory responses.
BPI Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the BPI locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within BPI. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt BPI function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of BPI-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.